CITIUS ONCOLOGY, INC. — Form 8-K
Filed August 14, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 68/100
What the filing says
Citius Oncology reported $7.1M revenue for nine months ended June 30, 2026 (vs. $0 prior year) following LYMPHIR's December 2025 FDA launch. Institutional vial orders grew 31% Q-o-Q to 926 units in Q3, with July 2026 reaching 383 vials—the largest month to date. The company raised $9.7M from warrant exercises and $10M from a $25M senior secured term loan facility; cash position is $16.6M as of June 30, 2026. Nine-month net loss was $41.1M ($0.42 per share) vs. $19.8M prior year, including a $19.7M one-time CMO contract cancellation charge. Commercial organization expanded to 29 people in August 2026.
Why this rating
Early revenue and accelerating institutional adoption of newly launched drug are meaningful for a $5.1M-market-cap biotech. However, $41M nine-month losses and modest absolute revenue ($7.1M) against burn rate create near-term cash concerns despite recent fundraising.
See more from August 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.